11C-PE2I and 18F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study

Research output: Contribution to journalArticle

Standard

11C-PE2I and 18F-Dopa PET for assessing progression rate in Parkinson's : A longitudinal study. / Li, Weihua; Lao-Kaim, Nick P.; Roussakis, Andreas A.; Marti´n-Bastida, Antonio; Valle-Guzman, Natalie; Paul, Gesine; Loane, Clare; Widner, Håkan; Politis, Marios; Foltynie, Tom; Barker, Roger A.; Piccini, Paola.

In: Movement Disorders, Vol. 33, No. 1, 01.2018, p. 117-127.

Research output: Contribution to journalArticle

Harvard

Li, W, Lao-Kaim, NP, Roussakis, AA, Marti´n-Bastida, A, Valle-Guzman, N, Paul, G, Loane, C, Widner, H, Politis, M, Foltynie, T, Barker, RA & Piccini, P 2018, '11C-PE2I and 18F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study', Movement Disorders, vol. 33, no. 1, pp. 117-127. https://doi.org/10.1002/mds.27183

APA

Li, W., Lao-Kaim, N. P., Roussakis, A. A., Marti´n-Bastida, A., Valle-Guzman, N., Paul, G., ... Piccini, P. (2018). 11C-PE2I and 18F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. Movement Disorders, 33(1), 117-127. https://doi.org/10.1002/mds.27183

CBE

Li W, Lao-Kaim NP, Roussakis AA, Marti´n-Bastida A, Valle-Guzman N, Paul G, Loane C, Widner H, Politis M, Foltynie T, Barker RA, Piccini P. 2018. 11C-PE2I and 18F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. Movement Disorders. 33(1):117-127. https://doi.org/10.1002/mds.27183

MLA

Vancouver

Li W, Lao-Kaim NP, Roussakis AA, Marti´n-Bastida A, Valle-Guzman N, Paul G et al. 11C-PE2I and 18F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. Movement Disorders. 2018 Jan;33(1):117-127. https://doi.org/10.1002/mds.27183

Author

Li, Weihua ; Lao-Kaim, Nick P. ; Roussakis, Andreas A. ; Marti´n-Bastida, Antonio ; Valle-Guzman, Natalie ; Paul, Gesine ; Loane, Clare ; Widner, Håkan ; Politis, Marios ; Foltynie, Tom ; Barker, Roger A. ; Piccini, Paola. / 11C-PE2I and 18F-Dopa PET for assessing progression rate in Parkinson's : A longitudinal study. In: Movement Disorders. 2018 ; Vol. 33, No. 1. pp. 117-127.

RIS

TY - JOUR

T1 - 11C-PE2I and 18F-Dopa PET for assessing progression rate in Parkinson's

T2 - A longitudinal study

AU - Li, Weihua

AU - Lao-Kaim, Nick P.

AU - Roussakis, Andreas A.

AU - Marti´n-Bastida, Antonio

AU - Valle-Guzman, Natalie

AU - Paul, Gesine

AU - Loane, Clare

AU - Widner, Håkan

AU - Politis, Marios

AU - Foltynie, Tom

AU - Barker, Roger A.

AU - Piccini, Paola

PY - 2018/1

Y1 - 2018/1

N2 - 18F-dopa PET measuring aromatic l-amino acid decarboxylase activity is regarded as the gold standard for evaluating dopaminergic function in Parkinson's disease. Radioligands for dopamine transporters are also used in clinical trials and for confirming PD diagnosis. Currently, it is not clear which imaging marker is more reliable for assessing clinical severity and rate of progression. The objective of this study was to directly compare 18F-dopa with the highly selective dopamine transporter radioligand 11C-PE2I for the assessment of motor severity and rate of progression in PD. Thirty-three mild-moderate PD patients underwent 18F-dopa and 11C-PE2I PET at baseline. Twenty-three were followed up for 18.8 ± 3.4 months. Standard multiple regression at baseline indicated that 11C-PE2I BPND predicted UPDRS-III and bradykinesia-rigidity scores (P < 0.05), whereas 18F-dopa Ki did not make significant unique explanatory contributions. Voxel-wise analysis showed negative correlations between 11C-PE2I BPND and motor severity across the whole striatum bilaterally. 18F-Dopa Ki clusters were restricted to the most affected putamen and caudate. Longitudinally, negative correlations were found between striatal (increment)11C-PE2I BPND, (increment)UPDRS-III, and (increment)bradykinesia-rigidity, whereas no significant associations were found for (increment)18F-dopa Ki. One cluster in the most affected putamen was identified in the longitudinal voxel-wise analysis showing a negative relationship between (increment)11C-PE2I BPND and (increment)bradykinesia-rigidity. Striatal 11C-PE2I appears to show greater sensitivity for detecting differences in motor severity than 18F-dopa. Furthermore, dopamine transporter decline is closely associated with motor progression over time, whereas no such relationship was found with aromatic l-amino acid decarboxylase. 11C-PE2I may be more effective for evaluating the efficacy of neuroprotective treatments in PD.

AB - 18F-dopa PET measuring aromatic l-amino acid decarboxylase activity is regarded as the gold standard for evaluating dopaminergic function in Parkinson's disease. Radioligands for dopamine transporters are also used in clinical trials and for confirming PD diagnosis. Currently, it is not clear which imaging marker is more reliable for assessing clinical severity and rate of progression. The objective of this study was to directly compare 18F-dopa with the highly selective dopamine transporter radioligand 11C-PE2I for the assessment of motor severity and rate of progression in PD. Thirty-three mild-moderate PD patients underwent 18F-dopa and 11C-PE2I PET at baseline. Twenty-three were followed up for 18.8 ± 3.4 months. Standard multiple regression at baseline indicated that 11C-PE2I BPND predicted UPDRS-III and bradykinesia-rigidity scores (P < 0.05), whereas 18F-dopa Ki did not make significant unique explanatory contributions. Voxel-wise analysis showed negative correlations between 11C-PE2I BPND and motor severity across the whole striatum bilaterally. 18F-Dopa Ki clusters were restricted to the most affected putamen and caudate. Longitudinally, negative correlations were found between striatal (increment)11C-PE2I BPND, (increment)UPDRS-III, and (increment)bradykinesia-rigidity, whereas no significant associations were found for (increment)18F-dopa Ki. One cluster in the most affected putamen was identified in the longitudinal voxel-wise analysis showing a negative relationship between (increment)11C-PE2I BPND and (increment)bradykinesia-rigidity. Striatal 11C-PE2I appears to show greater sensitivity for detecting differences in motor severity than 18F-dopa. Furthermore, dopamine transporter decline is closely associated with motor progression over time, whereas no such relationship was found with aromatic l-amino acid decarboxylase. 11C-PE2I may be more effective for evaluating the efficacy of neuroprotective treatments in PD.

UR - http://www.scopus.com/inward/record.url?scp=85032741980&partnerID=8YFLogxK

U2 - 10.1002/mds.27183

DO - 10.1002/mds.27183

M3 - Article

VL - 33

SP - 117

EP - 127

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 1

ER -